International
Stem Cell Corporation (OTCBB:ISCO)
(www.internationalstemcell.com),
announces that it has launched fifteen new human cell culture products
into the commercial research markets over the last twelve months through
its wholly-owned subsidiary, Lifeline Cell Technology, (Walkersville,
MD), leading to a 12-month average month-to-month revenue growth of 50%.
ISCO, the parent company, is the first company to create human
"parthenogenetic" stem cells from unfertilized eggs. Parthenogenetic
stem cells not only solve ethical problems, but also promise to minimize
immune-rejection by providing cells that can be immune-matched to large
segments of the population.
These products represent milestone achievements in ISCO's strategy of
generating revenue from the sale of research products, while building
infrastructure from that effort to expand the manufacturing and quality
control capacities ISCO needs to commercialize the therapeutic
applications of human parthenogenetic stem cells.
One of its newest and most promising products consist of "xeno-free"
human cells and culture reagents that allow researchers to study
embryonic stem cells without contamination from animal (non-human)
components. These products meet the needs for stem cell research to be
done using "human-only" systems. Other products include Lifeline's
living human cells and reagents for research and drug development into
cardiovascular, kidney, lung, nerve, eye and skin disease. Lifeline is
continuing to develop unique reagents and media for the growing field of
stem cell research. The "Lifeline" brand of products consist of human
cells and the culture reagents and growth factors needed to grow the
cells.
According to Jeffrey Janus, CEO of Lifeline, "We are proud of the
quality of our new products, as reflected in the sales growth they are
exhibiting in the human cell research markets. We look forward to
launching more new products into the growing markets for stem cell
research and drug development. These products will contribute to the
success of ISCO, not only by supporting ISCO's therapeutic research, but
also through the development of critical manufacturing and quality
control systems necessary for ISCO to produce therapeutic human cells in
the future."
Lifeline's products can be found at www.lifelinecelltechnology.com.
For more news and information on International Stem Cell Corporation
please visit www.IRGnews.com/coi/ISCO
where you can find the CEO's video, a fact sheet on the company,
investor presentations, and more. ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB):
International Stem Cell Corporation is a California biotechnology
company focused on developing therapeutic and research products. ISCO's
technology, Parthenogenesis, results in the creation of
pluripotent human stem cell lines from unfertilized human eggs. ISCO
scientists have created the first Parthenogenetic homozygous stem
cell line (phSC-Hhom-4) that can be a source of therapeutic cells
that will minimize immune rejection after transplantation into hundreds
of millions of individuals of differing sexes, ages and racial groups.
These advancements offer the potential to create the first true "Stem
Cell Bank" and address ethical issues by eliminating the need to use or
destroy fertilized embryos. ISCO also produces and markets specialized
cells and growth media worldwide for therapeutic research through its
subsidiary Lifeline Cell Technology. For more information, visit the
ISCO website at: www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications please click on
the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
FORWARD-LOOKING STATEMENTS: Statements pertaining to anticipated future financial and/or
operating results, future growth in research, technology, clinical
development and potential joint venture and other opportunities for the
company and its subsidiary, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements that
are not historical fact (including, but not limited to statements that
contain words such as "will," "believes," "plans," "anticipates,"
"expects," "estimates,") should also be considered to be forward-looking
statements. Forward-looking statements involve risks and uncertainties,
including, without limitation, risks inherent in the development and/or
commercialization of potential products, uncertainty in the results of
clinical trials or regulatory approvals, need and ability to obtain
future capital, application of capital resources among competing uses,
and maintenance of intellectual property rights. Actual results may
differ materially from the results anticipated in these forward-looking
statements and as such should be evaluated together with the many
uncertainties that affect the company's business, particularly those
mentioned in the cautionary statements found in the company's Securities
and Exchange Commission filings. The company disclaims any intent or
obligation to update these forward-looking statements.
Key Words: Stem Cells, Biotechnology, Cornea, Parthenogenesis
International Stem Cell Corporation Kenneth C. Aldrich, Chairman,
CEO 760-940-6383 kaldrich@intlstemcell.com or Lifeline
Cell Technology Jeffrey Janus, CEO janusj@lifelinecelltech.com or The
Investor Relations Group Laura Colontrelle 212-825-3210 lcolontrelle@investorrelationsgroup.com |